[Epalrestat].
Hotta
N
N
Third Department of Internal Medicine, Nagoya University School of Medicine.
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D001786:Blood Glucose / Q000378:metabolism; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D003929:Diabetic Neuropathies / Q000097:blood / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D005609:Free Radicals / Q000378:metabolism; D006442:Glycated Hemoglobin / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000097:blood; D006801:Humans; D015337:Multicenter Studies as Topic; D011498:Protein Precursors / Q000378:metabolism; D012236:Rhodanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D053778:Thiazolidines
D000449:Aldehyde Reductase; D001786:Blood Glucose; D004791:Enzyme Inhibitors; D005609:Free Radicals; D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D011498:Protein Precursors; D012236:Rhodanine; D053778:Thiazolidines; C040839:pre-hemoglobin A, glycosylated; C038131:epalrestat